A Guide to Stem Cell Transplant in Hematology

Published by Dr. Kasturi Mandal | Last updated: July 2025

Overview

A stem cell transplant (SCT), also known as a bone marrow transplant, is a procedure that replaces damaged or diseased bone marrow with healthy hematopoietic stem cells—the precursors to red blood cells, white blood cells, and platelets.

It is a critical treatment option in hematology for various blood cancers and disorders.

Indications in Hematology

Malignant (Cancerous) Disorders

Non-Malignant (Non-Cancerous) Disorders

  • Aplastic anemia
  • Thalassemia major & Sickle cell disease
  • Congenital immunodeficiencies

Types of Stem Cell Transplants

The main types are defined by the source of the stem cells:

  • 1. Autologous Transplant: Uses the patient’s own stem cells, which are collected and stored before high-dose therapy. This is common for multiple myeloma and lymphoma.
  • 2. Allogeneic Transplant: Uses stem cells from a healthy donor. This is necessary for leukemias, thalassemia, and aplastic anemia, as it provides a new, healthy immune system.

The Transplant Process

The process involves several key stages:

  1. Conditioning: The patient receives high-dose chemotherapy and/or radiation to destroy the diseased marrow and suppress the immune system.
  2. Infusion (Day 0): The healthy stem cells are infused into the patient's bloodstream, similar to a blood transfusion.
  3. Engraftment: Over the next 2–4 weeks, the new stem cells travel to the bone marrow, begin to grow, and produce new, healthy blood cells.

Risks and Complications

Stem cell transplants are complex procedures with significant risks, including infections during the period of low blood counts, bleeding, and organ toxicities. A major complication of allogeneic transplants is **Graft-versus-Host Disease (GVHD)**, where the donor's immune cells attack the patient's body. This is managed with immunosuppressive medications.

Recovery and Modern Advances

Recovery can take months or even years and requires close follow-up. However, outcomes continue to improve due to modern advances, including reduced-toxicity conditioning regimens, better management of GVHD, expanded use of alternative donors (like half-matched "haploidentical" donors), and exciting new fields like CAR-T cell therapy and gene-edited stem cells.

Trusted Resources